Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Erlotinib + Quinacrine
- Development stage
- Unknown
- Lead developer
- Astellas Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This combination involves **erlotinib**, a tyrosine kinase inhibitor used primarily in the treatment of non-small cell lung cancer (NSCLC), and **quinacrine**, an antimalarial drug that has shown potential in overcoming resistance to erlotinib by inhibiting the FACT complex and NF-κB transcriptional activity. The combination aims to enhance the efficacy of erlotinib in NSCLC by addressing resistance mechanisms.
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)SSRP1 (Facilitates chromatin transcription complex)
Beyond the preview
Go deeper on Erlotinib + Quinacrine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Erlotinib + Quinacrine.